{
  "url": "https://finance.yahoo.com/news/shaky-earnings-may-not-tell-044552456.html",
  "authorsByline": "Simply Wall St",
  "articleId": "f684cbb63c3945cba2a2fb3ffeb9ecdc",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T04:45:52+00:00",
  "addDate": "2025-08-25T05:19:35.856359+00:00",
  "refreshDate": "2025-08-25T05:19:35.856361+00:00",
  "score": 1.0,
  "title": "Shaky Earnings May Not Tell The Whole Story For YOC (ETR:YOC)",
  "description": "YOC AG's ( ETR:YOC ) weak earnings were disregarded by the market. While shares were up, we believe there are some...",
  "content": "YOC AG's (ETR:YOC) weak earnings were disregarded by the market. While shares were up, we believe there are some factors in the earnings report that might cause investors some concerns.\n\nAI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nOne key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF.\n\nThat means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.\n\nOver the twelve months to June 2025, YOC recorded an accrual ratio of 0.50. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of free cashflow in that time. Even though it reported a profit of \u20ac2.17m, a look at free cash flow indicates it actually burnt through \u20ac569k in the last year. It's worth noting that YOC generated positive FCF of \u20ac2.3m a year ago, so at least they've done it in the past. Having said that it seems that a recent tax benefit and some unusual items have impacted its profit (and this its accrual ratio).\n\nSee our latest analysis for YOC\n\nThat might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.\n\nThe Impact Of Unusual Items On Profit\n\nThe fact that the company had unusual items boosting profit by \u20ac228k, in the last year, probably goes some way to explain why its accrual ratio was so weak. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. If YOC doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4014162&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
    "https://simplywall.st/company/id/C4B17AB0-54CE-4B8D-8863-FB6C43004D36/past?blueprint=4014162&utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/YOC.DE",
    "https://simplywall.st/company/id/C4B17AB0-54CE-4B8D-8863-FB6C43004D36/past?blueprint=4014162&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/company/id/C4B17AB0-54CE-4B8D-8863-FB6C43004D36?blueprint=4014162&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "profit increases",
      "weight": 0.09673535
    },
    {
      "name": "lower profit",
      "weight": 0.09654972
    },
    {
      "name": "Profit",
      "weight": 0.09557226
    },
    {
      "name": "profit",
      "weight": 0.09557226
    },
    {
      "name": "Unusual Items",
      "weight": 0.09474095
    },
    {
      "name": "unusual items",
      "weight": 0.09474095
    },
    {
      "name": "less profit growth",
      "weight": 0.09076847
    },
    {
      "name": "free cash flow",
      "weight": 0.08653998
    },
    {
      "name": "high accruals ratios",
      "weight": 0.08574939
    },
    {
      "name": "future earnings",
      "weight": 0.085554816
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.990234375
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.98388671875
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.98095703125
    }
  ],
  "sentiment": {
    "positive": 0.15102342,
    "negative": 0.4683757,
    "neutral": 0.38060087
  },
  "summary": "YOC AG's weak earnings were largely ignored by the market, but there are concerns about the company's future performance. The accrual ratio, a financial ratio used to measure conversion of profit to free cash flow, is a key indicator of success. Over the twelve months to 2025, YOC recorded an acconsequential ratio of 0.50, indicating it did not generate any significant free cashflow in that period. The company had unusual items contributing \u20ac228k to its profit last year, which could potentially lead to lower profit or less growth. An interactive graph depicts future profitability based on these estimates.",
  "shortSummary": "YOC AG's weak earnings due to unusual items like a tax benefit and free cash flow have raised concerns about future profitability and profitability.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "9fb96045d386435cbf8aa790fd1b3410",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/company/id/C4B17AB0-54CE-4B8D-8863-FB6C43004D36/past?blueprint=4014162&utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo",
      "text": "YOC Past Earnings Performance\nPast criteria checks 2/6\nYOC has been growing earnings at an average annual rate of 29.3%, while the Interactive Media and Services industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 20.3% per year. YOC's return on equity is 28.6%, and it has net margins of 5.8%.\nKey information\n29.29%\nEarnings growth rate\n29.09%\nEPS growth rate\n| Interactive Media and Services Industry Growth | 17.00% |\n| Revenue growth rate | 20.26% |\n| Return on equity | 28.58% |\n| Net Margin | 5.76% |\n| Next Earnings Update | 17 Nov 2025 |\nRecent past performance updates\nRecent updates\nShareholders May Find It Hard To Justify A Pay Rise For YOC AG's (ETR:YOC) CEO This Year\nJul 10YOC's (ETR:YOC) Weak Earnings Might Be Worse Than They Appear\nJun 02Do YOC's (ETR:YOC) Earnings Warrant Your Attention?\nApr 05A Piece Of The Puzzle Missing From YOC AG's (ETR:YOC) 26% Share Price Climb\nFeb 27With EPS Growth And More, YOC (ETR:YOC) Makes An Interesting Case\nDec 31We Think YOC AG's (ETR:YOC) CEO Compensation Looks Fair\nJun 26YOC's (ETR:YOC) Earnings Are Weaker Than They Seem\nJun 03Investors Appear Satisfied With YOC AG's (ETR:YOC) Prospects As Shares Rocket 28%\nMay 22There Might Be More To YOC's (ETR:YOC) Story Than Just Weak Earnings\nNov 22When Should You Buy YOC AG (ETR:YOC)?\nOct 17With EPS Growth And More, YOC (ETR:YOC) Is Interesting\nMay 13If You Like EPS Growth Then Check Out YOC (ETR:YOC) Before It's Too Late\nApr 01Subdued Growth No Barrier To YOC AG (ETR:YOC) With Shares Advancing 29%\nDec 16Should You Be Adding YOC (ETR:YOC) To Your Watchlist Today?\nDec 03Revenue & Expenses Breakdown\nHow YOC makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 38 | 2 | 1 | 0 |\n| 31 Mar 25 | 36 | 3 | 1 | 0 |\n| 31 Dec 24 | 36 | 4 | 1 | 0 |\n| 30 Sep 24 | 36 | 4 | 1 | 0 |\n| 30 Jun 24 | 35 | 4 | 1 | 0 |\n| 31 Mar 24 | 34 | 3 | 1 | 0 |\n| 31 Dec 23 | 32 | 3 | 1 | 0 |\n| 30 Sep 23 | 29 | 2 | 0 | 0 |\n| 30 Jun 23 | 27 | 2 | 0 | 0 |\n| 31 Mar 23 | 25 | 2 | 0 | 0 |\n| 31 Dec 22 | 24 | 2 | 0 | 0 |\n| 30 Sep 22 | 23 | 2 | 0 | 0 |\n| 30 Jun 22 | 21 | 2 | 0 | 0 |\n| 31 Mar 22 | 20 | 2 | 0 | 0 |\n| 31 Dec 21 | 19 | 2 | 0 | 0 |\n| 30 Sep 21 | 18 | 1 | 0 | 0 |\n| 30 Jun 21 | 18 | 1 | 0 | 0 |\n| 31 Mar 21 | 16 | 1 | 0 | 0 |\n| 31 Dec 20 | 16 | 1 | 0 | 0 |\n| 30 Sep 20 | 15 | 1 | 0 | 0 |\n| 30 Jun 20 | 15 | 0 | 0 | 0 |\n| 31 Mar 20 | 16 | 0 | 0 | 0 |\n| 31 Dec 19 | 15 | 0 | 0 | 0 |\n| 30 Sep 19 | 15 | 0 | 0 | 0 |\n| 30 Jun 19 | 15 | 0 | 0 | 0 |\n| 31 Mar 19 | 14 | 0 | 0 | 0 |\n| 31 Dec 18 | 14 | 0 | 0 | 0 |\n| 30 Sep 18 | 14 | -1 | 1 | 0 |\n| 30 Jun 18 | 14 | -1 | 1 | 0 |\n| 31 Mar 18 | 14 | -1 | 1 | 0 |\n| 31 Dec 17 | 15 | -1 | 1 | 0 |\n| 30 Sep 17 | 14 | -1 | 1 | 0 |\n| 30 Jun 17 | 14 | -1 | 1 | 0 |\n| 31 Mar 17 | 13 | -1 | 1 | 0 |\n| 31 Dec 16 | 12 | -2 | 1 | 0 |\n| 30 Sep 16 | 11 | -2 | 1 | 0 |\n| 30 Jun 16 | 11 | -1 | 1 | 0 |\n| 31 Mar 16 | 10 | -2 | 1 | 0 |\n| 31 Dec 15 | 10 | -1 | 1 | 0 |\n| 30 Sep 15 | 9 | -2 | 1 | 0 |\n| 30 Jun 15 | 9 | -1 | 1 | 0 |\n| 31 Mar 15 | 10 | -1 | 1 | 0 |\n| 31 Dec 14 | 9 | -2 | 1 | 0 |\n| 30 Sep 14 | 10 | -2 | 1 | 0 |\nQuality Earnings: YOC has a high level of non-cash earnings.\nGrowing Profit Margin: YOC's current net profit margins (5.8%) are lower than last year (11.4%).\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: YOC's earnings have grown significantly by 29.3% per year over the past 5 years.\nAccelerating Growth: YOC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.\nEarnings vs Industry: YOC had negative earnings growth (-45.2%) over the past year, making it difficult to compare to the Interactive Media and Services industry average (0.08%).\nReturn on Equity\nHigh ROE: YOC's Return on Equity (28.6%) is considered high.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 05:13 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nYOC AG is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Benjamin Kohnke | Deutsche Bank |\n| Edward Acklin | First Berlin Equity Research GmbH |\n| Ingo Schmidt | Montega AG |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4014162&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nRakovina Therapeutics\nMarket Cap: US$10.8m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.37\n7D\n-9.8%\n1Y\nn/a\nCosmo Pharmaceuticals\nMarket Cap: US$924.5m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\nn/a\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$20.5m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$3.25\n7D\n12.8%\n1Y\n-79.3%\nImmunoPrecise Antibodies\nMarket Cap: US$147.7m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$3.20\n7D\n60.0%\n1Y\n295.1%\nEvolent Health\nMarket Cap: US$1.1b\nThrough its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.\nEVH\nUS$9.60\n7D\n6.4%\n1Y\n-69.6%\nGeneDx Holdings\nMarket Cap: US$3.7b\nA genomics company, provides genetic testing services.\nWGS\nUS$128.67\n7D\n2.2%\n1Y\n261.5%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.56\n7D\n-1.4%\n1Y\n3.1%\nSpectral AI\nMarket Cap: US$55.9m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$2.09\n7D\n-1.4%\n1Y\n43.2%\nRevenio Group Oyj\nMarket Cap: US$657.1m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.4b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$70.10\n7D\n5.7%\n1Y\n7.6%\nCareCloud\nMarket Cap: US$119.8m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$2.83\n7D\n4.0%\n1Y\n-0.7%\nSimulations Plus\nMarket Cap: US$293.3m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.57\n7D\n0.8%\n1Y\n-60.7%\nCeriBell\nMarket Cap: US$442.2m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$12.06\n7D\n-2.0%\n1Y\nn/a\nPerimeter Medical Imaging AI\nMarket Cap: US$26.2m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.17\n7D\n-1.4%\n1Y\n-39.1%\nNano-X Imaging\nMarket Cap: US$259.6m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$4.06\n7D\n-8.1%\n1Y\n-42.3%\nHeartSciences\nMarket Cap: US$13.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.65\n7D\n8.0%\n1Y\n-1.9%\nGuardant Health\nMarket Cap: US$7.7b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$61.40\n7D\n3.2%\n1Y\n129.6%\nOmniAb\nMarket Cap: US$227.0m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.85\n7D\n-8.0%\n1Y\n-57.8%\nBioXcel Therapeutics\nMarket Cap: US$72.5m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$4.98\n7D\n-9.1%\n1Y\n-54.2%\nXtalPi Holdings\nMarket Cap: US$40.9b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.20\n7D\n14.3%\n1Y\nn/a\nNeuroOne Medical Technologies\nMarket Cap: US$39.2m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.78\n7D\n-5.5%\n1Y\n-3.8%\nLantheus Holdings\nMarket Cap: US$4.0b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$58.21\n7D\n4.0%\n1Y\n-45.8%\nAbsci\nMarket Cap: US$483.3m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.63\n7D\n-10.2%\n1Y\n-41.4%\nHealwell AI\nMarket Cap: US$383.8m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.99\n7D\n4.2%\n1Y\n-34.9%\nPersonalis\nMarket Cap: US$428.3m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.83\n7D\n-0.4%\n1Y\n-16.7%\nVeradigm\nMarket Cap: US$823.7m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.85\n7D\n4.3%\n1Y\n-49.7%"
    },
    {
      "url": "https://simplywall.st/company/id/C4B17AB0-54CE-4B8D-8863-FB6C43004D36/past?blueprint=4014162&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "YOC Past Earnings Performance\nPast criteria checks 2/6\nYOC has been growing earnings at an average annual rate of 29.3%, while the Interactive Media and Services industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 20.3% per year. YOC's return on equity is 28.6%, and it has net margins of 5.8%.\nKey information\n29.29%\nEarnings growth rate\n29.09%\nEPS growth rate\n| Interactive Media and Services Industry Growth | 17.00% |\n| Revenue growth rate | 20.26% |\n| Return on equity | 28.58% |\n| Net Margin | 5.76% |\n| Next Earnings Update | 17 Nov 2025 |\nRecent past performance updates\nRecent updates\nShareholders May Find It Hard To Justify A Pay Rise For YOC AG's (ETR:YOC) CEO This Year\nJul 10YOC's (ETR:YOC) Weak Earnings Might Be Worse Than They Appear\nJun 02Do YOC's (ETR:YOC) Earnings Warrant Your Attention?\nApr 05A Piece Of The Puzzle Missing From YOC AG's (ETR:YOC) 26% Share Price Climb\nFeb 27With EPS Growth And More, YOC (ETR:YOC) Makes An Interesting Case\nDec 31We Think YOC AG's (ETR:YOC) CEO Compensation Looks Fair\nJun 26YOC's (ETR:YOC) Earnings Are Weaker Than They Seem\nJun 03Investors Appear Satisfied With YOC AG's (ETR:YOC) Prospects As Shares Rocket 28%\nMay 22There Might Be More To YOC's (ETR:YOC) Story Than Just Weak Earnings\nNov 22When Should You Buy YOC AG (ETR:YOC)?\nOct 17With EPS Growth And More, YOC (ETR:YOC) Is Interesting\nMay 13If You Like EPS Growth Then Check Out YOC (ETR:YOC) Before It's Too Late\nApr 01Subdued Growth No Barrier To YOC AG (ETR:YOC) With Shares Advancing 29%\nDec 16Should You Be Adding YOC (ETR:YOC) To Your Watchlist Today?\nDec 03Revenue & Expenses Breakdown\nHow YOC makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 38 | 2 | 1 | 0 |\n| 31 Mar 25 | 36 | 3 | 1 | 0 |\n| 31 Dec 24 | 36 | 4 | 1 | 0 |\n| 30 Sep 24 | 36 | 4 | 1 | 0 |\n| 30 Jun 24 | 35 | 4 | 1 | 0 |\n| 31 Mar 24 | 34 | 3 | 1 | 0 |\n| 31 Dec 23 | 32 | 3 | 1 | 0 |\n| 30 Sep 23 | 29 | 2 | 0 | 0 |\n| 30 Jun 23 | 27 | 2 | 0 | 0 |\n| 31 Mar 23 | 25 | 2 | 0 | 0 |\n| 31 Dec 22 | 24 | 2 | 0 | 0 |\n| 30 Sep 22 | 23 | 2 | 0 | 0 |\n| 30 Jun 22 | 21 | 2 | 0 | 0 |\n| 31 Mar 22 | 20 | 2 | 0 | 0 |\n| 31 Dec 21 | 19 | 2 | 0 | 0 |\n| 30 Sep 21 | 18 | 1 | 0 | 0 |\n| 30 Jun 21 | 18 | 1 | 0 | 0 |\n| 31 Mar 21 | 16 | 1 | 0 | 0 |\n| 31 Dec 20 | 16 | 1 | 0 | 0 |\n| 30 Sep 20 | 15 | 1 | 0 | 0 |\n| 30 Jun 20 | 15 | 0 | 0 | 0 |\n| 31 Mar 20 | 16 | 0 | 0 | 0 |\n| 31 Dec 19 | 15 | 0 | 0 | 0 |\n| 30 Sep 19 | 15 | 0 | 0 | 0 |\n| 30 Jun 19 | 15 | 0 | 0 | 0 |\n| 31 Mar 19 | 14 | 0 | 0 | 0 |\n| 31 Dec 18 | 14 | 0 | 0 | 0 |\n| 30 Sep 18 | 14 | -1 | 1 | 0 |\n| 30 Jun 18 | 14 | -1 | 1 | 0 |\n| 31 Mar 18 | 14 | -1 | 1 | 0 |\n| 31 Dec 17 | 15 | -1 | 1 | 0 |\n| 30 Sep 17 | 14 | -1 | 1 | 0 |\n| 30 Jun 17 | 14 | -1 | 1 | 0 |\n| 31 Mar 17 | 13 | -1 | 1 | 0 |\n| 31 Dec 16 | 12 | -2 | 1 | 0 |\n| 30 Sep 16 | 11 | -2 | 1 | 0 |\n| 30 Jun 16 | 11 | -1 | 1 | 0 |\n| 31 Mar 16 | 10 | -2 | 1 | 0 |\n| 31 Dec 15 | 10 | -1 | 1 | 0 |\n| 30 Sep 15 | 9 | -2 | 1 | 0 |\n| 30 Jun 15 | 9 | -1 | 1 | 0 |\n| 31 Mar 15 | 10 | -1 | 1 | 0 |\n| 31 Dec 14 | 9 | -2 | 1 | 0 |\n| 30 Sep 14 | 10 | -2 | 1 | 0 |\nQuality Earnings: YOC has a high level of non-cash earnings.\nGrowing Profit Margin: YOC's current net profit margins (5.8%) are lower than last year (11.4%).\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: YOC's earnings have grown significantly by 29.3% per year over the past 5 years.\nAccelerating Growth: YOC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.\nEarnings vs Industry: YOC had negative earnings growth (-45.2%) over the past year, making it difficult to compare to the Interactive Media and Services industry average (0.08%).\nReturn on Equity\nHigh ROE: YOC's Return on Equity (28.6%) is considered high.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 05:13 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nYOC AG is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Benjamin Kohnke | Deutsche Bank |\n| Edward Acklin | First Berlin Equity Research GmbH |\n| Ingo Schmidt | Montega AG |"
    },
    {
      "url": "https://simplywall.st/company/id/C4B17AB0-54CE-4B8D-8863-FB6C43004D36?blueprint=4014162&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
      "text": "YOC (YOC) Stock Overview\nOperates as a mobile advertising company in Germany and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 4/6 |\n| Future Growth | 5/6 |\n| Past Performance | 2/6 |\n| Financial Health | 5/6 |\n| Dividends | 0/6 |\nYOC Community Fair Values\nSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.\nYOC AG Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | \u20ac14.50 |\n| 52 Week High | \u20ac19.50 |\n| 52 Week Low | \u20ac13.00 |\n| Beta | 1.24 |\n| 1 Month Change | -9.38% |\n| 3 Month Change | -3.01% |\n| 1 Year Change | -23.28% |\n| 3 Year Change | -5.23% |\n| 5 Year Change | 281.58% |\n| Change since IPO | -16.43% |\nRecent News & Updates\nShareholders May Find It Hard To Justify A Pay Rise For YOC AG's (ETR:YOC) CEO This Year\nJul 10YOC's (ETR:YOC) Weak Earnings Might Be Worse Than They Appear\nJun 02Recent updates\nShareholders May Find It Hard To Justify A Pay Rise For YOC AG's (ETR:YOC) CEO This Year\nJul 10YOC's (ETR:YOC) Weak Earnings Might Be Worse Than They Appear\nJun 02Do YOC's (ETR:YOC) Earnings Warrant Your Attention?\nApr 05A Piece Of The Puzzle Missing From YOC AG's (ETR:YOC) 26% Share Price Climb\nFeb 27With EPS Growth And More, YOC (ETR:YOC) Makes An Interesting Case\nDec 31We Think YOC AG's (ETR:YOC) CEO Compensation Looks Fair\nJun 26YOC's (ETR:YOC) Earnings Are Weaker Than They Seem\nJun 03Investors Appear Satisfied With YOC AG's (ETR:YOC) Prospects As Shares Rocket 28%\nMay 22There Might Be More To YOC's (ETR:YOC) Story Than Just Weak Earnings\nNov 22When Should You Buy YOC AG (ETR:YOC)?\nOct 17With EPS Growth And More, YOC (ETR:YOC) Is Interesting\nMay 13If You Like EPS Growth Then Check Out YOC (ETR:YOC) Before It's Too Late\nApr 01Subdued Growth No Barrier To YOC AG (ETR:YOC) With Shares Advancing 29%\nDec 16Should You Be Adding YOC (ETR:YOC) To Your Watchlist Today?\nDec 03Shareholder Returns\n| YOC | DE Interactive Media and Services | DE Market | |\n|---|---|---|---|\n| 7D | 3.2% | -0.4% | 2.2% |\n| 1Y | -23.3% | 66.2% | 18.1% |\nReturn vs Industry: YOC underperformed the German Interactive Media and Services industry which returned 67.2% over the past year.\nReturn vs Market: YOC underperformed the German Market which returned 18% over the past year.\nPrice Volatility\n| YOC volatility | |\n|---|---|\n| YOC Average Weekly Movement | 5.1% |\n| Interactive Media and Services Industry Average Movement | 5.8% |\n| Market Average Movement | 5.1% |\n| 10% most volatile stocks in DE Market | 12.7% |\n| 10% least volatile stocks in DE Market | 2.5% |\nStable Share Price: YOC has not had significant price volatility in the past 3 months compared to the German market.\nVolatility Over Time: YOC's weekly volatility (5%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2000 | 125 | Dirk-Hilmar Kraus | www.yoc.com |\nYOC AG operates as a mobile advertising company in Germany and internationally. The company\u2019s products portfolio includes VIS X, a go-to-platform for programmatic advertising; YOC Inline Video Ad for sharing messages across display and video placements; and YOC Understitial Ad, a user-initiated format that allows the individual to reveal the ad by scrolling up or down.\nYOC AG Fundamentals Summary\n| YOC fundamental statistics | |\n|---|---|\n| Market cap | \u20ac50.41m |\n| Earnings (TTM) | \u20ac2.17m |\n| Revenue (TTM) | \u20ac37.67m |\nIs YOC overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| YOC income statement (TTM) | |\n|---|---|\n| Revenue | \u20ac37.67m |\n| Cost of Revenue | \u20ac29.96m |\n| Gross Profit | \u20ac7.71m |\n| Other Expenses | \u20ac5.54m |\n| Earnings | \u20ac2.17m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nNov 17, 2025\n| Earnings per share (EPS) | 0.62 |\n| Gross Margin | 20.47% |\n| Net Profit Margin | 5.76% |\n| Debt/Equity Ratio | 2.5% |\nHow did YOC perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 05:13 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nYOC AG is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Benjamin Kohnke | Deutsche Bank |\n| Edward Acklin | First Berlin Equity Research GmbH |\n| Ingo Schmidt | Montega AG |"
    }
  ],
  "argos_summary": "YOC AG reported weak earnings for the trailing twelve months, with a profit of \u20ac2.17\u202fmillion but a negative free\u2011cash\u2011flow of \u20ac569\u202fk, resulting in a high accrual ratio of 0.50 that signals potential future earnings pressure. Unusual items contributed \u20ac228\u202fk to the profit, raising concerns that the earnings growth may not repeat. The company\u2019s return on equity is strong at 28.6\u202f% and net margin at 5.8\u202f%, but its valuation and past performance are modest compared to the Interactive Media and Services industry. The article also highlights AI\u2019s transformative role in healthcare, listing 27 AI\u2011driven companies across diagnostics, drug discovery, and digital health, underscoring the sector\u2019s growth potential despite data privacy and integration challenges.",
  "argos_id": "IH1I0SIR8"
}